Reviva Pharmaceuticals Holdings Stock Fundamentals
| RVPH Stock | USD 1.49 0.04 2.76% |
Reviva Pharmaceuticals Holdings fundamentals help investors to digest information that contributes to Reviva Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Reviva Stock. The fundamental analysis module provides a way to measure Reviva Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Reviva Pharmaceuticals stock.
As of now, Reviva Pharmaceuticals' Other Operating Expenses is increasing as compared to previous years. The Reviva Pharmaceuticals' current Research Development is estimated to increase to about 33 M, while Interest Expense is projected to decrease to under 156.3 K. Reviva | Select Account or Indicator |
Reviva Pharmaceuticals Holdings Company Return On Equity Analysis
Reviva Pharmaceuticals' Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.
Current Reviva Pharmaceuticals Return On Equity | -17.95 |
Most of Reviva Pharmaceuticals' fundamental indicators, such as Return On Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Reviva Pharmaceuticals Holdings is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
For most industries, Return on Equity between 10% and 30% are considered desirable to provide dividends to owners and have funds for the future growth of the company. Investors should be very careful using ROE as the only efficiency indicator because ROE can be high if a company is heavily leveraged.
| Competition |
Reviva Total Stockholder Equity
Total Stockholder Equity |
|
Based on the latest financial disclosure, Reviva Pharmaceuticals Holdings has a Return On Equity of -17.9506. This is 25.11% lower than that of the Biotechnology sector and 50.77% lower than that of the Health Care industry. The return on equity for all United States stocks is notably higher than that of the company.
Reviva Pharmaceuticals Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Reviva Pharmaceuticals's current stock value. Our valuation model uses many indicators to compare Reviva Pharmaceuticals value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Reviva Pharmaceuticals competition to find correlations between indicators driving Reviva Pharmaceuticals's intrinsic value. More Info.Reviva Pharmaceuticals Holdings is rated below average in return on equity category among its peers. It also is rated below average in return on asset category among its peers . As of now, Reviva Pharmaceuticals' Return On Equity is decreasing as compared to previous years. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Reviva Pharmaceuticals' earnings, one of the primary drivers of an investment's value.Reviva Return On Equity Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Reviva Pharmaceuticals' direct or indirect competition against its Return On Equity to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Reviva Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Reviva Pharmaceuticals by comparing valuation metrics of similar companies.Reviva Pharmaceuticals is currently under evaluation in return on equity category among its peers.
Reviva Fundamentals
| Return On Equity | -17.95 | ||||
| Return On Asset | -1.91 | ||||
| Current Valuation | 28.84 M | ||||
| Shares Outstanding | 29.82 M | ||||
| Shares Owned By Insiders | 16.58 % | ||||
| Shares Owned By Institutions | 18.62 % | ||||
| Number Of Shares Shorted | 1.78 M | ||||
| Price To Book | 69.86 X | ||||
| EBITDA | (10.1 M) | ||||
| Net Income | (39.26 M) | ||||
| Cash And Equivalents | 23.19 M | ||||
| Cash Per Share | 1.13 X | ||||
| Total Debt | 17.98 M | ||||
| Current Ratio | 6.72 X | ||||
| Book Value Per Share | (0.05) X | ||||
| Cash Flow From Operations | (28.32 M) | ||||
| Short Ratio | 6.61 X | ||||
| Earnings Per Share | (1.59) X | ||||
| Target Price | 14.5 | ||||
| Number Of Employees | 15 | ||||
| Beta | -0.089 | ||||
| Market Capitalization | 43.24 M | ||||
| Total Asset | 23.7 M | ||||
| Retained Earnings | (134.35 M) | ||||
| Working Capital | 6.53 M | ||||
| Net Asset | 23.7 M |
About Reviva Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Reviva Pharmaceuticals Holdings's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Reviva Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Reviva Pharmaceuticals Holdings based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.| Last Reported | Projected for Next Year | ||
| Current Deferred Revenue | 2.5 M | 2.2 M | |
| Cost Of Revenue | 652.3 K | 579.8 K |
Currently Active Assets on Macroaxis
| CART | Maplebear Common Stock | |
| OPK | Opko Health | |
| AVAI | Avant Technologies | |
| VEOEY | Veolia Environnement SA | |
| GOOG | Alphabet Inc Class C |
Additional Information and Resources on Investing in Reviva Stock
When determining whether Reviva Pharmaceuticals is a strong investment it is important to analyze Reviva Pharmaceuticals' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Reviva Pharmaceuticals' future performance. For an informed investment choice regarding Reviva Stock, refer to the following important reports:Check out Reviva Pharmaceuticals Piotroski F Score and Reviva Pharmaceuticals Altman Z Score analysis. You can also try the Portfolio Manager module to state of the art Portfolio Manager to monitor and improve performance of your invested capital.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Reviva Pharmaceuticals. If investors know Reviva will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Reviva Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.59) | Return On Assets (1.92) | Return On Equity (17.95) |
The market value of Reviva Pharmaceuticals is measured differently than its book value, which is the value of Reviva that is recorded on the company's balance sheet. Investors also form their own opinion of Reviva Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Reviva Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Reviva Pharmaceuticals' market value can be influenced by many factors that don't directly affect Reviva Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Reviva Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Reviva Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Reviva Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.